IMGN on NASDAQ

ImmunoGen Inc.

Biotechnology company

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1981Founded1

Compare with UroGen Pharma Ltd., Theravance Biopharma, Inc. or ZEVRA THERAPEUTICS, INC., or pick any stock.

  • TickerIMGN on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham1
  • Websitewww.immunogen.com
  • Incorporated inMA5
  • Business address830 Winter St, Waltham, Ma 024515
  • Filer categoryLarge accelerated filer5
  • Legal formDomestic Business Corporation4
  • LEI54930084U0R1OP766Y024
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Craig Barrows, 02451 Waltham, United States4
  • Registered withCorporations Division (Secretary of the Commonwealth's Office), 0427266914

See how the biggest companies compare on our leaderboards

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-203.1%Operating margin7
-204.9%Net margin7
55.7%Revenue growth, 20227
-143.1%Return on equity7
-$231.2MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development65¢$213.4M
  • Selling, general and admin35¢$116.1M
  • Income tax0¢$1.2M

Out of $108.8M in revenue.7 The company lost money this year.

Financial statements

Revenue89107$108.8M in 2022+124% since 2016
0$50.0M$100.0M$150.0M2016: $48.6M$48.6M20162017: $115.4M$115.4M2017+137%2018: $53.4M$53.4M2018−54%2019: $82.3M$82.3M2019+54%2020: $132.3M$132.3M2020+61%2021: $69.9M$69.9M2021−47%2022: $108.8M$108.8M2022+56%
Operating income11129107-$220.9M in 2022+63% since 2016
-$300.0M-$200.0M-$100.0M02016: -$135.6M-$135.6M20162017: -$59.0M-$59.0M2017−57%2018: -$161.4M-$161.4M2018+174%2019: -$92.2M-$92.2M2019−43%2020: -$22.4M-$22.4M2020−76%2021: -$125.1M-$125.1M2021+459%2022: -$220.9M-$220.9M2022+77%
Net income11129107-$222.9M in 2022+42% since 2016
-$300.0M-$200.0M-$100.0M02016: -$156.7M-$156.7M20162017: -$96.0M-$96.0M2017−39%2018: -$168.8M-$168.8M2018+76%2019: -$104.1M-$104.1M2019−38%2020: -$44.4M-$44.4M2020−57%2021: -$139.3M-$139.3M2021+214%2022: -$222.9M-$222.9M2022+60%
Fiscal year2016201720182019202020212022
Revenue$48.6M8$115.4M8$53.4M9$82.3M10$132.3M7$69.9M7$108.8M7
Research and development$141.3M11$139.7M12$174.5M9$114.5M10$114.6M7$151.1M7$213.4M7
Selling, general and admin$38.6M7$43.8M7$116.1M7
Operating expenses$194.9M7$329.7M7
Operating income-$135.6M11-$59.0M12-$161.4M9-$92.2M10-$22.4M7-$125.1M7-$220.9M7
Income before tax-$139.3M7-$221.7M7
Income tax$012$09$010$07$07$1.2M7
Net income-$156.7M11-$96.0M12-$168.8M9-$104.1M10-$44.4M7-$139.3M7-$222.9M7
Earnings per share-$0.7010-$0.257-$0.687-$0.887
Earnings per share (diluted)-$0.7010-$0.257-$0.687-$0.887
Shares (weighted, basic)206.1M shares7253.6M shares7
Shares (weighted, diluted)206.1M shares7253.6M shares7

Compare ImmunoGen Inc. with another company

Leadership

Who has led ImmunoGen Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mitchel Sayare2006–2008
  2. Daniel M. Junius2009–2016
  3. Mark J. Enyedy2016–2024

Chair

  1. Mitchel Sayare2009

President

  1. Craig Barrows2010–2019

Chief financial officer

  1. Daniel M. Junius2006–2008
  2. Gregory D. Perry2009–2013
  3. Susan Altschuller2020–2022
  4. Lauren White2023–2024
1990200020102020
Board members and other officers (36)

Products and brands

Currently approved ADCs with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.

DM1 attached to an antibody with ImmunoGen's thioether linker is called "emtansine" in its INN name

trastuzumab emtansine, marketed as Kadcyla

DM1 attached to an antibody with ImmunoGen's SPP linker is called "mertansine".

Read the full text

DM4 attached with ImmunoGen's SPDB linker is called "ravtansine"

indatuximab ravtansine (BT062) targeting multiple myeloma,

anetumab ravtansine (BAY94-9343) targeting mesothelin (to treat mesothelioma), starting phase II trial in 2016

coltuximab ravtansine (SAR3419) targeting CD19 to treat acute lymphoblastic leukemia (ALL).

DM4 attached with ImmunoGen's sSPDB linker is called "soravtansine"

mirvetuximab soravtansine

ImmunoGen also developed isatuximab, a monoclonal antibody without linkage to a toxin.

From Wikipedia’s article on ImmunoGen, shared under CC BY-SA 4.0.6

Former names

  • IMMUNOGEN INCFeb 14, 1994 to Aug 5, 20195

Timeline

  1. May 19, 2016New chief executive Mark J. Enyedy becomes CEO15
  2. Jan 5, 2009New chief executive Daniel M. Junius becomes CEO16
  3. Feb 1, 2006New chief executive Mitchel Sayare becomes CEO17
  4. Mar 26, 1990Went public Listed on NASDAQ1
  5. 1981Founded Founded1

Filings

311 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 36 major events, 148 insider forms, 24 large holders, 94 other. The latest 20:

  1. Feb 22, 202415-12G EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Feb 14, 2024SC 13G/A EDGAR
  4. Feb 13, 2024SC 13G/A SCHEDULE 13G/A EDGAR
  5. Feb 12, 202425-NSE EDGAR
  6. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  7. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  8. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  9. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  10. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  11. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  12. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  14. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  16. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  17. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  18. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  19. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  20. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR

The 311 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 0 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 5, 2024Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale4,583$29.30$134.3KForm 4
Feb 5, 2024Wingrove TheresaSVP OF REGULATORY AFFAIRSSale12,027$29.30$352.4KForm 4
Feb 5, 2024Enyedy Mark JCHIEF EXECUTIVE OFFICERSale20,107$29.28$588.7KForm 4
Feb 5, 2024Lentini ReneeVP & PRIN ACCTG OFFICERSale2,631$29.30$77.1KForm 4
Jan 16, 2024Wingrove TheresaSVP OF REGULATORY AFFAIRSSale187,667$29.64$5.6MForm 4
Dec 26, 2023Lentini ReneeVP & PRIN ACCTG OFFICERSale6,548$29.74$194.7KForm 4
Dec 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale117,445$29.40$3.5MForm 4
Nov 30, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale3,826$29.20$111.7KForm 4
Nov 30, 2023Peterson KristineDirectorSale20,000$28.90$578.0KForm 4
Nov 30, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale164,424$28.95$4.8MForm 4
Nov 29, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale6,792$16.66$113.2KForm 4
Nov 17, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale78,223$16.05$1.3MForm 4
Nov 16, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale4,100$16.01$65.6KForm 4
Nov 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale166,725$15.85$2.6MForm 4
Nov 15, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale26,286$16.01$420.8KForm 4
Nov 7, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale19,517$16.66$325.2KForm 4
Nov 6, 2023Lentini ReneeVP & PRIN ACCTG OFFICERSale219,545$15.29$3.4MForm 4
Oct 16, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale192,004$14.40$2.8MForm 4
Sep 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale192,013$15.44$3.0MForm 4
Aug 9, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale100,210$14.20$1.4MForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62